NCT05150834

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines: Adenovirus-vectored Vaccine Versus mRNA Vaccine

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 53 (estimated)
• Sponsor: Korea University Guro Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.

Conditions

• Microbiome
• Vaccine
• Covid-19
• SARS-CoV-2
• Immunogenicity

Interventions

Type	Name	Description
OTHER	This is observational study	We enrolled the healthcare workers assigned to get either BNT162b2 or ChAdOx1 by the Korean government.

Timeline

• Start date: 2021-02-25
• Primary completion: 2021-07-16
• Completion: 2023-12-31
• First posted: 2021-12-09
• Last updated: 2021-12-09

Locations

1 site across 1 country: South Korea